Navigation Links
SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System
Date:5/19/2009

XUS Stent, the patency rate for the treated lesion was 92 percent. Restenosis was more common with distal lesions (90% patency) compared with non-distal lesions (98% patency). Reported in-stent late loss was low at 0.2 mm for non-distal lesions. The reported 15-month MACCE rate (all-cause death, stroke, myocardial infarction and revascularization) for the TAXUS Stent patients was 13 percent, driven primarily by a nine percent repeat revascularization rate.

For CABG patients, the overall obstruction/occlusion ratio at 15 months was 16 percent, with six percent of grafts obstructed in the range of (greater than or equal to)50% to (less than)100%, and 10 percent of grafts occluded 100%. On a per patient basis, the obstruction/occlusion ratio was 27 percent, with nine percent of patients having a graft obstructed in the (greater than or equal to)50% to (less than)100% range and 18 percent of patients having a graft occluded 100%. The reported MACCE rate for CABG patients at 15 months was nine percent.

"The data announced today from SYNTAX-LE MANS will offer important insights for doctors as they evaluate treatment options for challenging left main patients," said Keith Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "We are encouraged by the high stent patency rate at 15 months, which increases our confidence in the application of PCI in this high-risk population. The results support previously announced outcomes with PCI and CABG in patients with left main disease."

The safety and effectiveness of the TAXUS Express(2) Stent System have not been established in patients with left main or three-vessel disease.

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intend
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
2. Boston Scientific Welcomes Launch of Syntax Score Website
3. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
4. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
5. International Survey Shows People Over Forty Ignore Risk of Blindness
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
8. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
9. Video shows buckyballs form by shrink wrapping
10. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
11. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  EMD ... Merck KGaA, Darmstadt, Germany , ... Vice President, Head of Global Clinical Development.  Dr. ... expertise, including experience in Oncology and Immunology. She ... ability, having served as a Vice President in ...
(Date:4/16/2015)... and MENLO PARK, Calif. ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... in new orphan drug indications, today announced that the ... as a clinical trial site for the ongoing, multicenter ... glioblastoma multiforme (GBM), the most common and deadly form ...
(Date:4/16/2015)... , April 16, 2015  Northwest Biotherapeutics, Inc. ... company developing non-toxic DCVax® personalized immune therapies for ... in the Loncar Cancer Immunotherapy Index (LCINDX), a ... track the immunotherapy field within the biotechnology space.  ... "the top 25 companies" in the immunotherapy space, ...
(Date:4/16/2015)... Modality Solutions, a company that delivers ... industries, is pleased to announce its President, Gary ... Cold Chain IQ - Temperature Control Logistics and ... Global Cold Chain Connections, is dedicated to sharing ... pharmaceutical and healthcare supply chains. , Cold ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... ... delivers Market Leading Economies to Reduce Synthesis Costs and Increase Yields , ... Oceanside, CA (PRWEB) April 26, ... and the market leader in solid support for oligonucleotide synthesis, will be launching its ...
... computers are static. In our brains, information processing ... international research team from Japan and Michigan Technological ... evolution in an organic molecular layer that can ... a brain-like "evolutionary circuit" has been realized. ...
... SHANGHAI , April 23 /PRNewswire-Asia/ -- ... that it filed its annual report on Form 20-F for,the ... and Exchange Commission.,The annual report can be accessed on WuXi ... WuXi,PharmaTech will provide a hard copy of its annual report ...
Cached Biology Technology:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 2Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 3Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 4WuXi PharmaTech Files 2009 Annual Report on Form 20-F 2
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... group of chemical compounds used by a species of ... promising antimalarial properties for humans. The compounds are part ... to battle enemies and that may provide a ... novel analytical process, researchers at the Georgia Institute of ...
... successfully being used in clinical trials to treat patients with ... die, it also forces them to release pro-inflammatory chemokines and ... attack the disease. New research published by BioMed Central,s open ... infected cancer cells secrete proteins which, even when isolated, result ...
... Variations in skin color provide one of the best ... body and should be used to teach evolution in schools, ... level of interest in skin color and for teachers, that ... Nina Jablonski, professor and head, Department of Anthropology, Penn State. ...
Cached Biology News:Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4Skin color: Handy tool for teaching evolution 2Skin color: Handy tool for teaching evolution 3
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: